These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38417047)

  • 1. Association of Diabetic Retinopathy with Midlife Hepatic Steatosis Diagnosed by Elastography and Hepatic Steatosis Index in Type 2 Diabetes in an Indian Population.
    Mandal M; Ghosh S; Roy S; Mandal S; Dasgupta A
    Metab Syndr Relat Disord; 2024 Apr; 22(3):214-221. PubMed ID: 38417047
    [No Abstract]   [Full Text] [Related]  

  • 2. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus.
    Tan EZ; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2021 Mar; 36(3):751-757. PubMed ID: 32583444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of mid-life cerebral small vessel disease with diabetic retinopathy in type 2 diabetes in an Indian population.
    Karjee H; Ghosh S; Dhibar T
    J Diabetes Complications; 2022 Apr; 36(4):108149. PubMed ID: 35172935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.
    Lv WS; Sun RX; Gao YY; Wen JP; Pan RF; Li L; Wang J; Xian YX; Cao CX; Zheng M
    World J Gastroenterol; 2013 May; 19(20):3134-42. PubMed ID: 23716995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient elastography and controlled attenuation parameter to evaluate hepatic steatosis and liver stiffness in postpartum patients.
    Hussain FN; Rosenbluth E; Feldman KM; Strauss TS; Schneider E; Schmidt-Beauchat E; Rodriguez-Rivas C; Brustman L; Kushner T
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2190838. PubMed ID: 36935368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis.
    Sporea I; Mare R; Lupușoru R; Sima A; Sirli R; Popescu A; Timar R
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):167-74. PubMed ID: 27308647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
    Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach.
    Barana L; Nelva A; Scivetti P; Costanzo M; Fanelli CG
    Endocrine; 2024 May; 84(2):412-419. PubMed ID: 38347338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
    Demir M; Deyneli O; Yılmaz Y
    Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes.
    Fennoun H; Mansouri SE; Tahiri M; Haraj NE; Aziz SE; Hadad F; Hliwa W; Badr W; Chadli A
    Pan Afr Med J; 2020; 37():270. PubMed ID: 33598084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease.
    Ahn JM; Paik YH; Kim SH; Lee JH; Cho JY; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Korean Med Sci; 2014 Aug; 29(8):1113-9. PubMed ID: 25120322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes.
    Pozzan R; Pena RG; Palma CCSSV; de Carvalho Abi-Abib R; Terra C; Cobas RA
    Arch Endocrinol Metab; 2022 Sept 08; 66(4):452-458. PubMed ID: 35657127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.
    Roulot D; Roudot-Thoraval F; NKontchou G; Kouacou N; Costes JL; Elourimi G; Le Clesiau H; Ziol M; Beaugrand M
    Liver Int; 2017 Dec; 37(12):1897-1906. PubMed ID: 28556413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.